C12N 2310/322
2'-r modification
Official title: 2'-R Modification
C12N2310/322 (2'-r modification) appears on 1,518 US grants and 2,655 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,518
- Published applications
- 2,655
- Assignees
- 535
- Inventors
- 2,895
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 9 | 0 |
| 1996 | 24 | 0 |
| 1997 | 56 | 0 |
| 1998 | 62 | 0 |
| 1999 | 55 | 0 |
| 2000 | 44 | 0 |
| 2001 | 39 | 6 |
| 2002 | 39 | 28 |
| 2003 | 23 | 69 |
| 2004 | 18 | 64 |
| 2005 | 12 | 107 |
| 2006 | 12 | 44 |
| 2007 | 8 | 56 |
| 2008 | 8 | 37 |
| 2009 | 15 | 83 |
| 2010 | 36 | 62 |
| 2011 | 51 | 57 |
| 2012 | 44 | 68 |
| 2013 | 44 | 67 |
| 2014 | 34 | 54 |
| 2015 | 79 | 107 |
| 2016 | 52 | 113 |
| 2017 | 71 | 96 |
| 2018 | 61 | 92 |
| 2019 | 77 | 105 |
| 2020 | 59 | 114 |
| 2021 | 81 | 151 |
| 2022 | 80 | 184 |
| 2023 | 61 | 169 |
| 2024 | 88 | 246 |
| 2025 | 88 | 251 |
| 2026 | 81 | 225 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Antisense oligonucleotides for the treatment of stargardt disease29 Sep 2026US 12,747,440 B2ProQR Therapeutics II B.V.
- Compositions for delivery of antisense compounds22 Sep 2026US 12,741,989 B2Entrada Therapeutics, Inc.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
Most cited
By later US patents
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996